Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) EBIAT (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of EBIAT data on record, last reported at $802.0 million in Q4 2025.

  • For Q4 2025, EBIAT rose 3719.05% year-over-year to $802.0 million; the TTM value through Dec 2025 reached $909.0 million, up 12885.71%, while the annual FY2025 figure was $210.0 million, 2900.0% up from the prior year.
  • EBIAT reached $802.0 million in Q4 2025 per INDV's latest filing, up from $42.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $802.0 million in Q4 2025 and bottomed at -$97.0 million in Q2 2024.